The Direct Molecular Target for Imipridone ONC201 Is Finally Established

Shaomeng Wang1, David A Dougan2

  • 1Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Cancer Cell
|May 16, 2019
PubMed

Insights

Researchers found that activating ClpP, a cellular enzyme, is a promising cancer therapy strategy. The compound ONC201 effectively activates ClpP, leading to significant antitumor effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • ClpP is a bacterial and mitochondrial protease implicated in cellular regulation.
  • Dysregulation of ClpP activity has been observed in various cancer types.
  • Targeting ClpP presents a potential therapeutic avenue for cancer treatment.

Purpose of the Study:

  • To investigate the role of ClpP hyperactivation in cancer therapy.
  • To identify compounds that can activate ClpP.
  • To determine if ClpP activation mediates the antitumor effects of specific compounds.

Main Methods:

  • Screening for compounds that modulate ClpP activity.
  • Biochemical assays to confirm ClpP activation.
  • In vitro and in vivo studies to assess antitumor efficacy.

Main Results:

  • The clinical-stage compound ONC201 was identified as a potent activator of ClpP.
  • ONC201-induced ClpP activation was directly linked to its observed antitumor activity.
  • This activation mechanism offers a novel therapeutic strategy.

Conclusions:

  • Hyperactivation of ClpP is a viable strategy for cancer therapy.
  • ONC201's antitumor effects are mediated by ClpP activation.
  • Targeting ClpP represents a promising new direction in cancer treatment development.